Less than a month after the FDA’s Oncologic Drugs Advisory Committee voted 6‑3 to reject AstraZeneca’s camizestrant, Europe’s Committee for Medicinal Products for Human Use (CHMP) came to the opposite conclusion. The oral SERD, to be branded as Etcamah in Europe, is recommended with a CDK4/6 inhibitor for patients with ER‑positive, HER2‑negative locally advanced or metastatic breast cancer carrying ESR1 mutations. The FDA panel had questioned the SERENA‑6 trial design, despite a reported 56% improvement in progression‑free survival and a median 6.8‑month gain over standard aromatase inhibitor regimens. The agency has not yet ruled on U.S. approval. In the same session, the CHMP also endorsed Novo Nordisk’s once‑daily oral Wegovy pill for obesity after a 307‑patient pivotal study that showed an average 14% body‑weight reduction compared to 2% with placebo. Two very different outcomes, same week. Typical of current regulatory divergence.
This contrasting read on camizestrant highlights a widening trans‑Atlantic split in how regulators weigh oncology risk and evidence. Europe’s acceptance of PFS‑driven benefits signals a readiness to advance mechanism‑based innovation without waiting for mature survival data. The FDA, by contrast, is holding the line on traditional endpoints. For AstraZeneca, a European approval could preserve commercial traction in a SERD class that’s already crowded. If the U.S. decision mirrors the advisory vote, AstraZeneca will likely sequence its launch around Europe first and broaden combination trials to carve out differentiation. Investors are watching closely to see whether CHMP’s more permissive stance ripples back across the Atlantic, the two agencies have diverged before, especially in breast and lung cancers.
Meanwhile, the CHMP’s green light for oral Wegovy sets a European first for the GLP‑1 category. No injections, once‑daily dosing, though still some fasting rules that real‑world users may hate. The 14% mean weight loss is strong enough to reset expectations for what primary‑care management of obesity looks like, assuming reimbursement lands favorably. Competitors like Eli Lilly face growing pressure: its oral Foundayo already has U.S. clearance but hasn’t reached Europe. If Novo executes on manufacturing and payer access, 2026 could become the inflection point when oral GLP‑1s start transforming the obesity market from a niche specialty focus into mainstream chronic therapy. For the latest payer‑side rate dynamics, see RxPBM.ai. Then again, the story’s still unfolding, like most things in this space, it never stays still for long.
